IL7R α Specific Antibody for Treating of Acute Lymphoblastic Leukemia (ALL)

Researchers at the National Cancer Institute (NCI) have developed antibodies that selectively target IL-7R α, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases. The antibodies mediate leukemic cell killing through antibody-dependent cellular cytotoxicity (ADCC) and cause a significant reduction in T-ALL cell burden when administered in a xenograft m ouse model harboring patient derived leukemia. Researchers seek licensing and/or co-development research collaborations for further development of these antibodies.NIH Ref. No.: E-247-2015Advantages: • Selectively bind IL-7Rα with high (nanomolar) affinity• Mediates cancer cell killing through antibody-dependent cellular cytotoxicity (ADCC)• Targeted therapy with potential for fewer and less severe adverse events• Well-established regulatory path• Numerous approved products using same approach (e.g., Rituximab – targeting CD20 expressed in B-cell non-Hodgkin lymphoma (NHL), and Cetuximab – targeting EGFR/ErbB1 in metastatic colorectal and head and neck cancersApplications: • Targeted therapy for various cancers including T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL)• Targeted therapy for several autoimmune disorders (Type 1 diabetes and multiple sclerosis) • Organ transplant rejection• Type 1 diabetes• Multiple sclerosisDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 7, ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research